RMTI News & Events

Sees Q4 gross margin 22%, up from 14% in Q3. Sees Q4 cash flow from operations $2.3M, which represents the second cash flow positive quarter in 2025. As a result, cash and cash equivalents and investments available-for-sale at December 31, 2025 are expected to increase to approximately $25M. "Our preliminary financial results for the fourth quarter 2025 reflect our unrelenting drive towards making Rockwell Medical a profitable company and positioning the Company for long-term stability and success," said Mark Strobeck, CEO. "We saw a considerable increase in revenue, were cash flow positive, were Adjusted EBITDA positive, and we improved our cash position. Additionally, we continued to improve on our operational efficiencies and reduce expenses, which resulted in a gross margin of 22% in Q4, representing a notable improvement over every quarter in 2025. As we look to 2026, we are focused on three main areas: revenue growth, increased profitability, and portfolio diversification."

Rockwell Medical announced that the company has added 30 new customers in the western portion of the United States. The Western U.S. now accounts for more than 10% of the company's customer clinic footprint.

Rockwell Medical announced that the Amended and Restated Product Purchase Agreement dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States has been extended through December 31, 2026. As part of the Amended Agreement, product pricing will be increased for the extended term.